newsfilter
← Latest News
GlobeNewswire·

ObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedings

Transition of linzagolix program to Kissei Pharmaceutical Co., Ltd. substantially complete with approximately $16.0 million savings expected from assignment of program contracts, including $3.7 million of accounts